Fluorescent Guide Can ID Tumor Missed by Standard Lumpectomy
23 May 2023
Clinical Result
TUESDAY, May 23, 2023 -- For patients with stages 0 to 3 breast cancers, pegulicianine fluorescence-guided surgery (pFGS) can enhance the efficacy of lumpectomy surgery, according to a study published online April 27 in NEJM Evidence.
Barbara L. Smith, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues conducted a prospective trial to examine margin status with or without intraoperative pFGS for stages 0 to 3 breast cancers. Patients were randomly assigned 10:1 to pFGS or control groups to prevent surgeons from performing smaller than standard lumpectomies in anticipation of pFGS assistance. In patients undergoing pFGS, at sites of pegulicianine signal, additional pFGS-guided cavity margins were excised. The percentage of patients for whom pFGS-guided margins contained cancer, sensitivity, and specificity were examined as coprimary end points.
Four hundred six patients received 1.0 mg/kg intravenous pegulicianine followed by lumpectomy. Of 392 patients randomly assigned, 316 and 76 had invasive cancers and in situ cancers, respectively. The researchers found that pFGS-guided margins removed tumor left behind after standard lumpectomy in 27 of 357 patients undergoing pFGS, 22 from cavity orientations deemed negative on standard margin evaluation. In nine of 62 patients with positive margins, second surgeries were avoided by pFGS. PFGS specificity was 85.2 percent on per-margin analysis, and sensitivity was 49.3 percent. In six patients, pegulicianine administration was stopped for adverse events.
"We found that pFGS removed tumor missed by standard lumpectomy and reduced the need for second surgeries for positive margins," Smith said in a statement. "Given its potential, pFGS merits evaluation in future trials and studies."
Several authors disclosed ties to biopharmaceutical companies, including Lumicell, which funded the study.
Abstract/Full Text
Posted May 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.